Scleroderma Treatment Guidelines

Introduction to Scleroderma Treatment

The American College of Rheumatology recommends an organ-specific approach targeting the affected systems, with methotrexate combined with systemic corticosteroids being the first-line therapy for active, potentially disfiguring or disabling forms of scleroderma 1, 2

The European League Against Rheumatism recommends dihydropyridine-type calcium channel blockers, such as oral nifedipine, as first-line therapy for Raynaud's phenomenon 3
Phosphodiesterase-5 (PDE-5) inhibitors should be considered for treatment of SSc-related Raynaud's phenomenon and digital ulcers, according to the American College of Cardiology 1, 3
Intravenous iloprost should be considered for severe Raynaud's phenomenon that fails to respond to oral therapy, as suggested by the European Society of Cardiology 3
Fluoxetine may be used for SSc-related Raynaud's phenomenon as an alternative treatment option, according to the American College of Rheumatology 1, 3
Treatment options for SSc-related PAH include endothelin receptor antagonists, prostacyclin analogues, PDE-5 inhibitors, and riociguat, as recommended by the American Thoracic Society 1, 4
For rapidly progressive SSc with skin and/or lung involvement, hematopoietic stem cell transplantation may be considered in selected patients, according to the European Society for Blood and Marrow Transplantation 1, 4
Prokinetic agents may be beneficial for GI motility disorders, as suggested by the American Gastroenterological Association 1

Standardized assessment using the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) is recommended to evaluate disease activity and damage, according to the American Academy of Dermatology 2, 5
Classification based on subtype, extent, and depth should guide treatment decisions, as recommended by the European Academy of Dermatology and Venereology 2
For limited, superficial lesions (circumscribed morphea), topical treatments are generally sufficient, according to the American Academy of Dermatology 2
Medium-dose UVA1 therapy is effective in improving skin softness and reducing thickness, as suggested by the European Academy of Dermatology and Venereology 6, 2
Methotrexate (MTX) at 15 mg/m²/week (oral or subcutaneous) combined with systemic corticosteroids during the initial inflammatory phase is recommended as first-line therapy for linear, deep, generalized, or pansclerotic morphea, according to the American College of Rheumatology 2, 5

Regular clinical assessment using standardized tools is essential to monitor disease activity and response to treatment, as recommended by the American College of Rheumatology 2, 5
Close monitoring for medication side effects, particularly with MTX which may cause nausea, headache, and transient hepatotoxicity, is necessary, according to the European League Against Rheumatism 2
MTX or alternative disease-modifying drugs should be withdrawn once the patient is in remission and off steroids for at least 1 year, as suggested by the American College of Rheumatology 6, 2

The European League Against Rheumatism recommends cyclophosphamide for skin involvement, quality of life, and function in patients with systemic sclerosis, with a moderate strength of evidence 7
Uncontrolled and retrospectively controlled studies with immunosuppressive regimens have reported efficacy in selected manifestations of systemic sclerosis, including azathioprine, mycophenolate mofetil, and ciclosporine A 7
Caution is necessary when using cyclosporine as it may decrease renal function and induce hypertension, with a moderate strength of evidence 8

The American College of Rheumatology suggests that medications that are truly disease-modifying for systemic sclerosis in terms of mortality are lacking, and the efficacy of treatments is often only modest to moderate 8
Patients with systemic sclerosis should be referred to a specialized center due to the heterogeneity of the disease, the complexity of diagnostic evaluation, and the wide array of available treatment options, as recommended by the European League Against Rheumatism 8